There is information missing from the Competing Interests statement. The correct Competing Interests statement is as follows: N.A. was a consultant for Cepheid, and has licensed a biomarker for early detection of pancreas cancer to Cepheid (PATENT # 10167513). N.A also has grant funding from Astex Pharmaceuticals (GRANT # 120039). N.A. has served as a consultant to Johnson and Johnson, as an advisor to Celgene, and as a member of the Scientific Advisory Council to the No Stomach for Cancer Foundation. H.K. reviewed the manuscript; he is a scientific contributor and Vice President at Astex Inc. This does not alter our adherence to PLOS ONE policies on sharing data and materials.
Reference
- 1. Thakar M, Hu Y, Morreale M, Lerner L, Ying Lin W, Sen R, et al. (2018) A novel epigenetic modulating agent sensitizes pancreatic cells to a chemotherapy agent. PLoS ONE 13(6): e0199130. https://doi.org/10.1371/journal.pone.0199130 pmid:29927979
Citation: Thakar M, Hu Y, Morreale M, Lerner L, Lin WY, Sen R, et al. (2020) Correction: A novel epigenetic modulating agent sensitizes pancreatic cells to a chemotherapy agent. PLoS ONE 15(11): e0242974. https://doi.org/10.1371/journal.pone.0242974
Published: November 20, 2020
Copyright: © 2020 Thakar et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.